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Abstract Botanicals are an alternative option to pre-
scription drugs for the alleviation of symptoms due to
anxiety disorders and insomnia. Melissa ofﬁcinalis L. has
been shown as an anti-stress and anxiolytic agent. We
previously reported moderate stress improvement in mice
in which Cyracos
, a standardized Melissa ofﬁcinalis L.
extract, was administrated. Cyracos
 contains phyto-
chemicals that inhibit gamma-aminobutyric acid catabo-
lism. This was a prospective, open-label, 15-day study to
evaluate the efﬁcacy of Cyracos
 on stressed volunteers,
who have mild-to-moderate anxiety disorders and sleep
disturbances. Using clinician rating criteria, primary out-
comes showed improvement of symptoms. Cyracos

reduced anxiety manifestations by 18% (p\0.01), ame-
liorated anxiety-associated symptoms by 15% (p\0.01)
and lowered insomnia by 42% (p\0.01). As much as 95%
of subjects (19/20) responded to treatment, of which 70%
(14/20) achieved full remission for anxiety, 85% (17/20)
for insomnia, and 70% (14/20) for both. Our study dem-
onstrates, for the ﬁrst time that chronic administration of
Melissa ofﬁcinalis L. relieves stress-related effects. It is
critical that further studies incorporate a placebo and
investigate physiological stress markers.
Keywords Melissa ofﬁcinalis L.  Anxiety  Insomnia 
Free Rating Scale for Anxiety (FRSA)  Hamilton Rating
Scale for Depression (HRSD)  Gamma-aminobutyric acid
(GABA)
Introduction
Anxiety comprises behavioral, cognitive and physiological
responses to threatening situations or uncertainty, and is
deﬁned as an unpleasant emotional state for which the
cause is not readily identiﬁable or perceived to be uncon-
trollable or unavoidable [1]. Anxiety often manifests as
debilitating chronic conditions, which can develop at an
early age or appear suddenly after a triggering event. Such
conditions are prone to ﬂare-up at times of high stress and
are frequently accompanied by physiological and psycho-
logical symptoms, including somatic (e.g., headache,
sweating, muscle spasms, palpitations, and hypertension)
and psychosomatic (e.g., mental confusion, compulsory
obsessive behaviors and emotional instability) changes,
which, in certain cases, lead to fatigue and exhaustion [2].
Stress represents an interaction between an environ-
mental stimulus (stressor) and a stress response system,
such as the hypothalamic–pituitary–adrenal (HPA) axis
and catecholamines [1]. Individuals who are exposed to
stressful conditions exhibit autonomic responses, such as
changes in heart rate and body temperature, in addition to
behavioral responses that are related to elevated anxiety
and endocrine responses [3]. Consequently, anxiety can
constitute a component of a potential stressor [1].
Activation of the stress system induces insomnia.
Moreover, when insomnia is chronic and severe, it develops
into a stressor [4]. Insomnia is a heterogeneous disorder that
entails difﬁculties with sleep onset, maintenance and early
J. Cases  N. Feuille `re  M. Roller
Naturex SA, BP 1218, 84911 Avignon, France
A. Ibarra (&)
Naturex Inc., 375 Huyler Street, South Hackensack,
NJ 07606, USA
e-mail: a.ibarra@naturex.us
S. G. Sukkar
Dietetics and Clinical Nutrition Unit,
San Martino University Hospital, Largo Rosanna Benzi 10,
16132 Genoa, Italy
123
Mediterr J Nutr Metab (2011) 4:211–218
DOI 10.1007/s12349-010-0045-4morning wakening [5]. Subjective complaints of decreased
duration of sleep or diminished sleep quality, depth and
efﬁciency are also typical deﬁnitions of insomnia [6].
A myriad of evidence indicates that drug medications
that are often used to treat anxiety and insomnia result in
adverse effects that are related to acquired tolerance and
withdrawal from the drug [7, 8]. Botanical treatments that
have been developed as alternatives are known to induce
calming effects [8, 9]. Consequently, traditional botanical
extracts (e.g., valerian, lime blossoms, passiﬂora, and
lemon balm) have been developed commercially, because
their efﬁcacy is rarely linked to side effects [10–12]. Thus,
a botanical extract that treats anxiety should certainly be a
component of the treatment regimen for anxiety-induced
disorders and sleep disturbance. These properties exist in a
Melissa ofﬁcinalis L. (lemon balm) leaf extract that has
been standardized to contain more than 5% hydroxycin-
namic acid content [13].
Melissa ofﬁcinalis L. improves cognitive performance
and mood [14, 15], reduces induced stress [16] and has
anxiolytic effects [17] in humans. These studies, however,
were conducted using acute treatment with the botanical,
and to date there are no published clinical trials of
Melissa ofﬁcinalis L. extract for the treatment of chronic
manifestations. Recently, we reported novel anxiolytic-
like effects under moderate stress-induced conditions in
mice that were administered Cyracos
 chronically for
15 days [18]. Cyracos
 contains rosmarinic acid and the
pentacyclic triterpenoids, ursolic and oleanolic acids [18],
which inhibit gamma-aminobutyric acid (GABA) catabo-
lism [19, 20]. Due to its efﬁcacy in improving anxiety
under moderate stress, Cyracos
 may be a valuable
alternative to pharmaceutical drugs in treating anxiety
disorders.
Although the open-label design is unable to rule out
placebo effects from those of Cyracos
, this pilot study
was aimed to estimate the improvement of symptoms in the
treatment of stressed volunteers, who are affected with
mild-to-moderate anxiety disorders and sleep disturbances,
but are otherwise healthy.
Materials and methods
Volunteers
Participants were recruited through advertisements and
from the outpatient Dietetics and Clinical Nutrition Unit
of San Martino University Hospital, Genoa, Italy. Vol-
unteers who met DSM-IV-TR criteria [21] for a primary
diagnosis of anxiety disorders and sleep disturbances were
eligible.
Volunteers who met at least one exclusion criterion were
not enrolled into the trial. Exclusion criteria included:
pregnancy, lactation, intention to become pregnant during
the course of the study or volunteers of child-bearing
potential not using adequate contraception; consumption of
anti-anxiety drugs, antidepressants, hypnoinducers or sed-
atives 10 days before the start of the study; diabetes;
asthma; hypo- and hyperthyroidism; depression; severe
obsessive–compulsive disturbances; schizophrenia; psy-
chosis in general; consumption of serotonin-reuptake
inhibitors drugs.
Design
Institutional review board approval was obtained as well as
written informed consent from all volunteers prior to ini-
tiation of the study. The trial was conducted in accordance
with the Declaration of Helsinki, Good Clinical Practice
guidelines and the Italian drug law.
A prospective, single-center, open-label study was
conducted on 20 stressed volunteers (outpatients; 6 male,
14 female) between the ages of 18 and 70 years, who were
affected by mild-to-moderate anxiety disorders and sleep
disturbances, but were otherwise healthy. All volunteers
were treated with Cyracos
.
Treatment
Cyracos

Cyracos
 (Naturex, SA, France) is a hydroalcoholic
Melissa ofﬁcinalis L. leaf extract that has been standard-
ized to consist of more than 7% rosmarinic acid and greater
than 15% hydroxycinnamic acid derivatives [18].
Table 1 summarizes the content of the principal phyto-
chemical compounds in Cyracos
 compared with Melissa
ofﬁcinalis L. leaves and extracts, as published. The values
for Cyracos
 were derived from ﬁve industrial batches
[mean ± standard error of the mean (SEM)], manufactured
at Naturex SA, Site d’Agroparc BP 1218-84911 Avignon,
France. Samples of Cyracos
 were also analyzed with
regard to their hydroxycinnamic acid [18], ﬂavonoid [22]
and triterpene pentacyclic acid [18] content.
Cyracos
 administration
Each volunteer took 600 mg of Cyracos
 per day, divided
into two doses: one tablet in the morning and another in
the evening before falling asleep. Each tablet contained
66.67% Cyracos
 (300 mg), 18.89% maltodextrin, 11.11%
microcrystalline cellulose, 1.56% stearate magnesium,
1.11% talc and 0.66% micronized silica.
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Primary outcomes for anxiety disorders and insomnia
Volunteers were interviewed using a test that was based on
the Free Rating Scale for Anxiety (FRSA) to evaluate anx-
iety and its associated symptoms [23] and on the Hamilton
RatingScaleforDepression(HRSD)toassessinsomnia[24]
at baseline (pre-administration) and at the end of the
study (post-administration) to evaluate the overall clinical
change in symptoms. The 20-question test was divided into
three categories: anxiety manifestations, anxiety-associated
symptoms and insomnia. Insomnia was further categorized
intoinitial,middleanddelayed.Table 2showsthescalesand
deﬁnitions that were used for each test category.
The Clinical Global Impression-Improvement scale
(CGI-I) was used to measure volunteers’ overall clinical
improvementinanxietydisordersandsleepdisturbancesover
the 15-day treatment trial. The CGI-I consists of a clinical
rating of a patient’s overall improvement in symptoms as
compared to baseline, with scores ranging from 1 (‘‘very
muchimproved’’)to7 (‘‘verymuchworse’’)[25].Treatment
responders were deﬁned as those volunteers whose GI end-
point score was B2 (‘‘much’’ or ‘‘very much improved’’).
Safety
Adverse events were evaluated at each study visit by
directly asking volunteers if they experienced any adverse
events or illness.
Statistical analysis
All values were expressed as mean (M) ± standard error to
the mean (SEM). Statistical analyses were performed using
analysisofvariancewithanonparametricWilcoxonrank-sum
test,two-tailedandalphasetat0.001level(ExcelStat,2008).
Statistical signiﬁcance was set to p\0.05 and p\0.01.
Results
Efﬁcacy and safety
Cyracos
 treatment demonstrated a signiﬁcant improve-
ment in all categories studied: anxiety manifestations,
anxiety-associated symptoms and insomnia.
The following results are based on a scale of 0–3 for
anxiety manifestations and anxiety-associated symptoms
Table 1 Chief phytochemicals
in Cyracos
 (mean ± SEM of
ﬁve industrial batches) and
Melissa ofﬁcialis L. leaves and
extracts, as reported in literature
a [38],
b[39],
c[40],
d[41],
e[22],
f[42],
g[43],
h[44],
i[45]
Compounds Cyracos
,% Melissa ofﬁcinalis L.
Leaves
(fresh and dried), %
Extracts, %
Hydroxycinnamates
Rosmarinic acid 7.95 ± 0.29 0.52–4.60
a,b,c,d 2.21–9.65
b,e,f
Total hydroxycinnamates 18.50 ± 0.63 11.29
e 7.01–12.51
b,e,f
Flavonoids
Hesperidin 0.23 ± 0.01 – 0.93
e
Luteolin-3-glucuronide 0.46 ± 0.04 0.54
b 0.18–0.51
b,f
Total ﬂavonoids 0.69 ± 0.04 0.45–1
e,g 0.23
f
Triterpenes
Oleanolic acid 0.22 ± 0.03 0.06–0.45
h,i –
Ursolic acid 0.64 ± 0.09 0.21–0.58
i –
Table 2 Scales used in the 20-Question Inventory that is based on the Free Rating Scale for Anxiety (FRSA) to evaluate anxiety and its
associated symptoms, and on the Hamilton Rating Scale for Depression (HRSD) to assess insomnia
Anxiety
manifestations
Anxiety-associated
symptoms
Insomnia
Initial Middle Delayed
0 = Absent 0 = Absent 0 = Absent 0 = Absent 0 = Absent
1 = Mild to
moderate
1 = Mild to moderate 1 = Taking 35–45 min to fall
asleep
1 = Restless nights 1 = Early awakening at
dawn
2 = Moderate 2 = Moderate 2 = Always difﬁculty falling
asleep
2 = Wakening during the
night
2 = Wakening at dawn
3 = Severe 3 = Severe
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insomnia with 2 having maximum severity. Values were
obtained before and after the 15-day administration of
Cyracos
.
Cyracos
 was well tolerated by the studied population.
No adverse effects were observed and all volunteers
complied with the treatment until the end of the study.
Primary outcomes
Anxiety disorders
Anxiety manifestations Agitation decreased by 35%
(1.30 ± 0.16 vs. 0.25 ± 0.10, p\0.01), hyperactivity by
10% (0.40 ± 0.11 vs. 0.10 ± 0.07, p\0.05) and tension
by 18% (0.70 ± 0.18 vs. 0.15 ± 0.08, p\0.01). Motor
disturbances, however, declined marginally by 10%
(0.45 ± 0.15 vs. 0.15 ± 0.08, p\0.08; see Fig. 1).
Total anxiety manifestations were reduced by 18%
(p\0.01), from 0.71 ± 0.10 to 0.16 ± 0.06, representing
an improvement from mild-to-moderate anxiety to the
absence of measurable anxiety.
Anxiety-associated symptoms Several parameters of
anxiety-associated symptoms were greatly reduced, such as
eating problems, which were lowered by 33% (1.60 ± 0.22
vs. 0.60 ± 0.15, p\0.01), emotional instability by 7%
(0.25 ± 0.12 vs. 0.05 ± 0.05, p\0.05), fatigue by 18%
(0.80 ± 0.20 vs. 0.25 ± 0.10, p\0.01), feelings of guilt
by 15% (0.60 ± 0.20 vs. 0.15 ± 0.08, p\0.01), feeling
of inferiority by 18% (0.80 ± 0.20 vs. 0.25 ± 0.10,
p\0.01), intellectual disturbance by 28% (1.05 ± 0.17
vs. 0.20 ± 0.09, p\0.01), muscular reactions by 13%
(0.50 ± 0.15 vs. 0.10 ± 0.07, p\0.01), poor interper-
sonal relationships by 13% (0.65 ± 0.23 vs. 0.25 ± 0.14,
p\0.01) and psychosomatic symptoms by 33% (1.05 ±
0.18 vs. 0.05 ± 0.05, p\0.01). To a lesser extent, the
following symptoms were reduced: obsessive–compulsive
behavior by 5% (0.35 ± 0.18 vs. 0.20 ± 0.12, p\0.05),
speech problems by 3% (0.10 ± 0.07 vs. 0.00 ± 0.00,
p\0.05) and vague somatic symptoms by 8% (0.50 ±
0.15 vs. 0.25 ± 0.10, p\0.05). Skin reactions were not
reported before or after the treatment (see Fig. 2).
In total, anxiety-associated symptoms declined by 15%
(p\0.01), from 0.63 ± 0.10 to 0.18 ± 0.04, representing
an improvement from a mild-to-moderate level of symp-
toms to their absence.
Insomnia
All measurements for insomnia were greatly reduced at the
end of the study. Initial insomnia decreased by 53%
(1.55 ± 0.11 vs. 0.50 ± 0.11, p\0.01), middle insomnia
by 45% (1.20 ± 0.14 vs. 0.30 ± 0.11, p\0.01) and
delayed insomnia by 28% (0.65 ± 0.17 vs. 0.30 ± 0.06,
p\0.01; see Fig. 3).
In total, insomnia was reduced by 42% (p\0.01), from
1.13 ± 0.10 to 0.30 ± 0.06, representing an improvement
from difﬁculty in falling asleep to having minimal to no
difﬁculties.
Clinical rating of improvement
Based on CGI improvement scores, 19 volunteers out of 20
demonstrated a clinically signiﬁcant positive treatment
response for anxiety disorders; 14 volunteers reached full
remission of symptoms; 5 volunteers responded to treat-
ment with signiﬁcant symptom improvement but not full
remission; one patient minimally improved (see Table 3).
For insomnia, 20 volunteers out of 20 demonstrated a
clinically signiﬁcant positive treatment response; 17 volun-
teers reached full remission of symptoms; 3 volunteers
responded to treatment with signiﬁcant symptom improve-
ment but not full remission (see Table 3).
Discussion
In this open-label pilot study, based on the rapid rate of
response by volunteers to treatment with Cyracos
, there
was signiﬁcant improvement of associated symptoms of
anxiety and insomnia.
Anxiety is a psychological and physiological condition
that is characterized by cognitive, somatic, emotional and
0
1
2
3
Agitation
Hyperactivity
Motor 
disturbance
Tension
Pre-administration
Post-administration
**
* * *
Fig. 1 Anxiety manifestations before and after 15 days of treatment
with 600 mg Cyracos
 (300 mg twice a day) in 20 volunteers
affected by anxiety disorders and sleep disturbances. *p\0.05;
**p\0.01
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anxiety are governed primarily by the limbic system of the
brain. At this level, the amygdala is the area that is asso-
ciated with the assignment of emotions, especially anxiety
[26].
Physiologically, the amygdala manages the primary
inputs of the nucleus accumbens, which comprises pri-
marily medium spiny neurons that are special types of
inhibitory cells [27, 28]. The neurotransmitter that is pro-
duced by these neurons is GABA [29]. Thus, it appears that
anxiety is modulated by GABA levels in the brain.
Accordingly, the GABAergic system is a logical and
promising target of new strategies to prevent and treat anx-
iety and its associated symptoms, such as restlessness and
insomnia. GABA activity is mediated through GABAA and
GABAB receptor-dependent inhibition of the CNS, and
GABA catabolism relies on GABA transaminase (GABA-T)
levels [30].
0
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2
3
Eating problem
Emotional
instability
Fatigue
Guilty feelings
Feeling of
inferiority
Intellectual
disturbance
  Muscular
reactions
Obsessive-
compulsive
behavior
Poor
interpersonal
relationships
Psychosomatic
Skin reaction
Speech
problems
Vague somatic
Pre-administration
Post-administration
**
*
**
**
**
**
**
**
**
*
*
*
Fig. 2 Anxiety-associated
symptoms before and after
15 days of treatment with
600 mg Cyracos
 (300 mg
twice a day) in 20 volunteers
affected by anxiety disorders
and sleep disturbances.
*p\0.05; **p\0.01
0
1
2
Initial
Middle Delayed
Pre-administration
Post-administration
**
** **
Fig. 3 Insomnia parameters before and after 15 days of treatment
with 600 mg Cyracos
 (300 mg twice a day) in 20 volunteers
affected by anxiety disorders and sleep disturbances. **p\0.01
Table 3 Outcome of treatment with Cyracos
 at endpoint using the
CGI-I scale for determination of clinical improvement of anxiety and
insomnia symptoms
Outcome Anxiety Insomnia
n % n %
Responder 19 95 20 100
Nonresponder 1 5 0 0
Very much improved 14 70 17 85
Much improved 5 25 3 15
Minimally improved 1 5 0 0
No change 0 0 0 0
Minimally worse 0 0 0
Much worse 0 0 0 0
Very much worse 0 0 0 0
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123Kennedyetal.[16]ﬁrstproposedthatMelissaofﬁcinalisL.
exerts its anxiolytic effect and modulates mood through the
GABAergic system. Recently, this proposed mechanism was
examined in a preliminary screen of traditional anxiolytic
botanical extracts [19], wherein the aqueous extract of
Melissa ofﬁcinalis L. effected the greatest inhibition of
GABA-Tactivity.Inaseparatestudy,thesamegroupisolated
and identiﬁed rosmarinic acid and the triterpenoids pentacy-
clic ursolic acid and oleanolic acid as potent inhibitors of
GABA-T [20].
Because the increase in GABAergic neurotransmission
has been associated with reductions in anxiety, its associated
symptoms and insomnia, the behavioral study in this work
was aimed at determining the anti-anxiety effects of Melissa
ofﬁcinalis L. extract, Cyracos
. Our results demonstrate that
chronic administration of Cyracos
 300 mg twice daily for
15 days signiﬁcantly improved the psychological status of
male and female volunteers who were affected by mild-to-
moderate anxiety disorders and sleep disturbances. Holisti-
cally, this amelioration represented a shift in the distressed
volunteers from having mild-to-moderate feelings of irrita-
tiontoaneartotalattenuationofmanifestations,asevidenced
by the disappearance of signiﬁcant signs, such as anxiety, its
symptoms andinsomniaafter15 days oftreatment.Thiswas
also highlighted with a huge rate of responders.
With regard to the modulation of the manifestations of
anxiety, total anxiety manifestations in the volunteers
decreasedby18%after15 daysoftreatmentcomparedtothe
baseline score. These positive effects, which contributed to
the improvement of anxietydisorders, conﬁrm results from a
recent study in which mice that were administered Cyracos

for 15 days improved their behavior signiﬁcantly under
moderate stress conditions [18]. The authors proposed a
mechanism of action through the GABAergic pathway,
involvinginhibitionofGABA-Tandleadingtoanincreasein
GABA availability in the brain. The phytochemicals that
wereimplicatedinthisproposedmechanismwererosmarinic
acid and the triterpenoid pentacyclic acids, ursolic and ole-
anolic, as previously reported [18, 20].
At the appropriate dose, Cyracos
 inhibits GABA-T
activity and therefore has anxiolytic-like effects [18, 20],
whereas at too high a dose, it contributes signiﬁcantly to
increased anxiety and negative mood, as demonstrated in a
study of rosmarinic acid on the behavior of mice under
stressful conditions [31] and in a clinical trial on the anx-
iolytic effects of Melissa ofﬁcinalis L. throughout induced
stress [17].
With regard to overall anxiety-associated symptoms,
Cyracos
 treatment resulted in a signiﬁcant improvement
after 15 days, decreasing symptoms by 15% compared
with baseline score. Notably, emotional instability, intel-
lectual disturbances, and psychosomatic symptoms and
speech problems improved.
These results constitute novel ﬁndings in a prospective
observational chronic human trial, complementing a pre-
vious study on the attenuation of induced stress after acute
administration of Melissa ofﬁcinalis L. extract [16]. In this
prior study, the authors suggested that the botanical
improved stress-induced adverse effects and increased the
speed of mathematical processing, which was linked easily
to a decrease in intellectual disturbances, similar to our
observations. Moreover, such manifestations were also
reported to correlate closely with the many physical
symptoms that develop in anxiety-affected subjects [32].
The positive effects of Melissa ofﬁcinalis L. leaf extract
in the present study on fatigue, muscular reactions and
improvement in vague somatic symptoms can be connected
to the antinociceptive properties of Melissa ofﬁcinalis L.
extract and rosmarinic acid, as demonstrated in a chemi-
cally induced nociception animal model [33]. In addition to
these ﬁndings, Singh eliminated the possibility of any
organic-based link in these volunteers and recommended
that the presence of acute psychosocial stressors during
anxiety should be studied more thoroughly [32].
We performed such an examination with the modiﬁed
FRSA in this study. Notably, the decrease in anxiety
manifestations was associated with a signiﬁcant decline in
the primary psychosocial symptoms after 15 days of
treatment, as demonstrated by signiﬁcant decrease in eating
problems, feelings of guilt and inferiority, obsessive–
compulsive behavior and poor interpersonal relationships.
These measures have been reported to be governed by a
mechanism that involves the HPA axis [34], in which
inhibition is thought to be mediated by GABA levels [35].
Consequently, whereas a small increase in GABAergic
activity due to chronic Melissa ofﬁcinalis L. extract intake
might be sufﬁcient to reduce moderate anxiety levels sig-
niﬁcantly, it might be ineffective during more stressful
situations, depending on relative stress-induced HPA axis
responses.
This open-label prospective study demonstrated that
there was a signiﬁcant improvement in insomnia after
15 days of treatment, which decreased by 42% compared
with the baseline score. Amelioration of initial, middle, and
delayed insomnia was observed, with volunteers showing
improvement from having moderate levels of difﬁculties
with falling asleep and restless nights to a level in which
they were unaffected, corresponding to nights with no
difﬁculties and full rest. Although it was not signiﬁcant
before the study, the rate of awakening also decreased after
15 days of treatment.
Theseresultsconﬁrmpreviousreportsthathavesuggested
that600 mgofMelissaofﬁcinalisL.leafextractperdayisthe
appropriate dose to improve sleep parameters in healthy
volunteers [36]. These ﬁndings are also consistent with the
German Commission E recommendations regarding the
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insomnia[37]. However, although Cyracos
 led to symptom
improvement, the 15-day duration and the small sample size
did not address the long-term efﬁcacy and limited the inter-
pretation of the signiﬁcance of the study ﬁndings. It is pos-
sible that contact with the clinician contributed to part of the
symptom improvement observed. Testing Cyracos
 in a
larger sample using placebo-controlled designs and a longer
time period will be critical to prove its effectiveness. Nev-
ertheless, our study demonstrates that 600 mg Cyracos
,
administrated in two daily doses for 15 days, is safe.
Conclusion
The present open-label prospective study investigated the
effects of Cyracos
 administration; innovative results
provide some evidence that the treatment might be bene-
ﬁcial to humans affected by mild-to-moderate anxiety
disorders and sleep disturbance. For the ﬁrst time, chronic
Melissa ofﬁcinalis L. leaf extract treatment has been
demonstrated to improve mild-to-moderate anxiety disor-
ders, its associated symptoms and insomnia in humans.
Future studies, however, must incorporate a placebo arm,
extend the number of subjects and examine the physio-
logical stress markers of the HPA axis to verify the pro-
posed mechanism of regulation by Melissa ofﬁcinalis L.
leaf extract through the GABAergic pathway. The extent to
which its therapeutic effects depend on the availability and
amounts of various constituents in the extract is unknown;
nevertheless, many studies have reported rosmarinic acid
and pentacyclic triterpenoid acids to mediate these effects
through GABA metabolism [20].
Based on a psychosocial approach, these results and
those from a previous work by Ibarra et al. [18] suggest a
robust effect of Cyracos
 on anxiety and insomnia.
Moreover, the absence of sedatives and signiﬁcant side
effects render Cyracos
 a viable option for mild-to-mod-
erate anxiety disorder subjects. Therefore, they can avoid
drugs, such as benzodiazepines, barbiturates and antide-
pressants, the use of which has been discouraged due to
their soporiﬁc effects and other serious side effects,
including acquired tolerance.
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